GlassScriptPhysician profile
Bashir O Attuwaybi
NPI 1578791992
$6,010.78
in general payments reported to CMS, 2019-2025
13 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $224 · 2021: $125 · 2022: $180 · 2023: $181 · 2024: $4,194 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,265 · Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,264.52 |
| Food and Beverage | $734.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,033.70 | 2020-2024 | |
| Stryker Corporation | $747.01 | 2019 | |
| Abbvie INC. | $467.95 | 2020-2025 | Rinvoq, Linzess, Creon |
| Medtronic USA, INC. | $161.49 | 2019-2020 | |
| Axonics, INC. | $122.53 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.61 | 2024-2025 | Entyvio |
| Janssen Biotech, INC. | $102.65 | 2023-2024 | Stelara, Tremfya |
| Medical Device Business Services, INC. | $89.01 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $70.50 | 2022-2024 | Fujifilm |
| Ferring Pharmaceuticals INC. | $65.34 | 2019-2023 | Rebyota |
| Olympus America INC. | $17.00 | 2019 | |
| Gilead Sciences, INC. | $15.85 | 2024 | |
| Medtronic, INC. | $14.14 | 2025 | Ligasure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashir Attuwaybi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.